Hypertension Clinical Trial
Official title:
In-depth Study of the Cost-effectiveness of the Risk Assessment and Management Programme for Hypertension (RAMP-HT) for Patients With Uncontrolled Hypertension in Primary Care in Hong Kong
Hypertension (HT) is an important risk factor for stroke, coronary heart disease (CHD), heart
failure and renal diseases, and the leading risk factor of global disease burden. A multitude
of interventions have proven efficacy in lowering blood pressure and reducing long term HT
complications, including pharmacologic treatment, DASH diet (Dietary Approaches to Stop
Hypertension), exercise, weight reduction, smoking cessation, alcohol moderation and
self-monitoring of blood pressure.
Objectives:
To evaluate long-term effectiveness and cost-effectiveness of
Risk-Assessment-and-Management-Programme-for-Hypertension (RAMP-HT), a multi-disciplinary
structured service to enhance quality of hypertension care in primary care compared to usual
care
Hypotheses:
1. RAMP-HT is effective in reducing HT complications, based on previous results showing
RAMP-HT was effective in improving patients' blood pressure
2. RAMP-HT is cost-effective
Design and Subjects:
Retrospective study of 5-year longitudinal data on matched cohorts of public primary care
patients with uncontrolled HT under RAMP-HT and usual care will be conducted to evaluate
long-term effectiveness and direct medical costs. Results from the long-term effectiveness
and costing analyses will be applied to Markov modeling to determine the life time
cost-effectiveness of RAMP-HT.
Main outcome measures:
1. 5-year incidence of cardiovascular complications
2. Direct medical costs of RAMP-HT and usual care HT patients
3. Incremental cost-effectiveness ratio (ICER) of cost per quality-adjusted life year
(QALY) gained by RAMP-HT compared to usual care
Data analysis:
Cox regression will be performed to estimate the effect of RAMP-HT on the development of HT
complication adjusted for baseline covariates. Descriptive statistics will be used to
calculate costs of RAMP-HT and annual direct medical costs for HT patients. Markov modeling
will be used to simulate 2 patient cohorts (RAMP-HT versus usual care) to estimate the
respective lifetime direct medical costs and QALY gained/person. Cost/QALY of RAMP-HT will be
compared to that of usual care to determine the ICER.
Expected results:
The results can provide evidence on the effectiveness and cost-effectiveness of RAMP-HT for
primary care patients with uncontrolled HT, which can inform health policy and service
planning.
Aim and objectives:
The aim of this study is to evaluate the cost-effectiveness of the RAMP-HT of the HA in
primary care patients with uncontrolled hypertension.
The objectives are to:
1. Evaluate the long term (5-year) effectiveness of RAMP-HT compared to usual care in
reducing cardiovascular complications, end-stage renal disease and all-cause mortalities
in a cohort of primary care patients with uncontrolled hypertension at baseline
2. Estimate the direct medical cost of RAMP-HT and other health services among primary care
HT patients with or without complications
3. Evaluate the cost-effectiveness of RAMP-HT, compared to usual care, in gaining one QALY
in primary care patients with uncontrolled hypertension
Hypotheses:
1. RAMP-HT is more effective in reducing 5-year cardiovascular complications, end stage
renal disease and all-cause mortality among primary care patients with uncontrolled
hypertension compared to usual care
2. The direct medical cost of RAMP-HT patients, for the same disease complication status,
is not higher than that of usual care except for the RAMP-HT cost
3. The direct medical cost of HT patients with one or more complications is higher than
that of HT patients without any complication
4. RAMP-HT is cost-effective compared to usual care, i.e. ICER per QALY gained is below the
threshold value of 1 annual GDP (Gross Domestic Product) per capita of Hong Kong, which
is the benchmark recommended by the World Health Organization
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
| Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
| Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
| Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
| Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Recruiting |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
| Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
| Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
| Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
| Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
| Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
| Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
| Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
| Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
| Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
| Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |